Given To Launch Next-Gen Colonoscopy PillCam In Europe In November
This article was originally published in The Gray Sheet
Executive Summary
Given Imaging expects its PillCam COLON 2 endoscopy capsule will overcome many of the limitations identified in a recent clinical trial comparing its first-generation PillCam COLON to standard colonoscopy
You may also be interested in...
Covidien Ventures Into Capsule-Based Endoscopy With Given Imaging Acquisition
The $860 million purchase agreement will give Covidien the dominant capsule endoscopy platform on the market as the company hopes for FDA approval this year of PillCam COLON 2 as a less invasive alternative for patients who are unable to undergo a colonoscopy.
Reimbursement Briefs: PillCam Reimbursement In Japan; 3-D Mammo Code Withdrawn; CMS Data Sharing
Japan will reimburse PillCam COLON. 3-D mammography CPT code application withdrawn from AMA CPT Editorial Panel meeting. CMS unveils new virtual research data-sharing tool.
Given Imaging’s PillCam Colon 2 Strategy Shift Will Delay Screening Claim
Firm initially will pursue diagnostic imaging claim for its PillCam Colon 2 video capsule, rather than a screening claim, as the fastest route to U.S. market. The strategy shift follows preliminary clinical trial data review.